Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Afatinib for LMD in EGFR+ NSCLC
NCT03711422Phase 1Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoints: Afatinib concentration in plasma, Afatinib concentration in Cerebral Spinal Fluid at Day 31 and 3 more. Started Nov 2018; status: terminated.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03711422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711422.